Artificial Intelligence

Cradle

Medium1/3 relationships sourcedProfile verified Aug 14, 2026
OverviewSourcesM&A fitRelationship mapStoryMilestones

30-Second Executive Brief

Executive Assessment

Cradle functions as a regional institution within Artificial Intelligence, backed by 47% sourcing coverage, with a stable competitive position.

  • Maintains 3 mapped relationships across the graph
  • 47% sourcing coverage across sourced relationships
  • Tracked as regional institution within the Artificial Intelligence category

Executive Snapshot

Strategic Role
Regional Institution
Sourcing Coverage
47%
View Methodology →

Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.

Ecosystem Influence
Moderate
Strategic Momentum
Insufficient Data

Coverage

Mapped Relationships
3
Technology Domains
4

Strategic Implications

  • Central node connecting multiple strategic ecosystems
  • Directly influences technology and capital flows
  • Material relevance to downstream dependency mapping

Top Opportunities

Continued expansion across top-25 pharma customer base beyond current six relationshipsCase-study-driven adoption growth as protein-engineering campaigns demonstrate faster, cheaper results

Top Risks

Optimization-platform approach depends on continued adoption by existing biotech R&D teams rather than owning end-to-end drug programsCompetitive category with well-funded foundation-model rivals (EvolutionaryScale) and applied-biologics rivals (Earendil Labs)

Critical Dependencies

Continue to Dependency Graph ↓

An AI protein engineering software company whose enterprise-grade platform serves six of the top 25 global pharma companies across more than 50 R&D programs. Cradle raised a $73 million Series B to advance its AI protein engineering software, with customers using the platform to speed up early R&D projects by up to 12x and reduce costs by up to 90%; recent case studies include improving a Staphylococcus aureus vaccine's thermostability by 2.5°C in a single optimization round, seven times faster than rational design.

⚡

Sources

Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.

Evidence

1 source

  • PR Newswire — Cradle's AI protein engineering platform serves six of top 25 pharma leaderscompany
⚡

Acquisition & Investment Fit

AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.

⚡

Relationship Map

The relationships surrounding Cradle — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.

2 levels3 levels 🔒5 levels 🔒

Connection type

Sign in free to click a node and explore →

Click any node to make it the new center. Scroll to zoom, drag to pan.

⚡

The Story So Far (last 6 months)

Jun 2026: Cradle's AI protein engineering platform serves six of top 25 pharma leaders→Aug 2026: Cradle's software-tooling model trades program-level upside for broader, lower-risk distr… (unconfirmed)

Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.

Market Intelligence

Unverified

Credibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.

Cradle's software-tooling model trades program-level upside for broader, lower-risk distribution across pharma

27% confidence

Cradle's enterprise software model serves six of the top 25 global pharma companies across 50+ R&D programs with a smaller $73 million Series B raise, a materially different economics profile than program-owning peers like Earendil Labs that capture milestone-based licensing revenue.

This is InsightNodes' own interpretive read: unlike Earendil Labs, which owns and licenses its own drug programs for milestone payments, Cradle sells optimization software to existing pharma R&D teams -- a model that scales faster across six of the top 25 global pharma companies and 50+ programs but caps Cradle's upside to subscription/service revenue rather than the multi-billion-dollar milestone payouts available to platforms that own their own biologics pipeline.

InsightNodes analysis of Cradle's platform economics · Aug 14, 2026

AI Protein Design & Synthetic BiologyEarendil LabsEvolutionaryScale
⚡

Cradle's Timeline

A sourced, dated history of Cradle's key moments — founding to present.

  1. Jan 2021 · Founded

    Cradle was founded to build AI-powered protein engineering software for biotech and pharma R&D teams.

  2. Nov 2024 · Raises $73M Series B

    Cradle raised a $73 million Series B round to advance its AI protein engineering software platform.